UniProtKB/Swiss-Prot Q9NQ40 : Variant p.Ile303Val
Solute carrier family 52, riboflavin transporter, member 3
Gene: SLC52A3
Feedback ?
Variant information
Variant position:
303
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
LB/B
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Isoleucine (I) to Valine (V) at position 303 (I303V, p.Ile303Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Other resources:
Links to websites of interest for the variant.
Sequence information
Variant position:
303
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
469
The length of the canonical sequence.
Location on the sequence:
QGQGYLEEKAAPCCPAHLAF
I YTLVAFVNALTNGMLPSVQT
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human QGQGYLEEKAAPCCPAHLAFI YTLVAFVNALTNGMLPSVQT
Mouse PGKGSVEASVASLRPAQLAFI YSVVAFVNALTNGVLPSVQT
Rat PGKGSVEVSVASLRPAQLAFI YSVVAFVNALTNGVLPSVQT
Bovine KAQDPPEEKTAPQHLAHLTFI YVLVAFVNALTNGVLPSVQT
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
1 – 469
Solute carrier family 52, riboflavin transporter, member 3
Transmembrane
293 – 313
Helical
Literature citations
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1); VARIANTS LEU-267; MET-278 AND VAL-303;
Brown-Vialetto-van Laere and Fazio-Londe overlap syndromes: a clinical, biochemical and genetic study.
Ciccolella M.; Catteruccia M.; Benedetti S.; Moroni I.; Uziel G.; Pantaleoni C.; Chiapparini L.; Bizzi A.; D'Amico A.; Fattori F.; Salsano M.L.; Pastore A.; Tozzi G.; Piemonte F.; Bertini E.;
Neuromuscul. Disord. 22:1075-1082(2012)
Cited for: VARIANTS BVVLS1 ASP-58; TRP-266; SER-319 AND ALA-413; VARIANT VAL-303;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.